Research advances in correlation between liver diseases and oral microbiota_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

JI Xiao ^1,2 , ZENG Yanglin ² , GUO Yafan ² , KONG Lingxiang ¹ ,  YANG Jiayin ¹

1. Center of Organ Transplantation, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
2. West China School of Stomatology, Sichuan University, Chengdu 610041, P. R. China;

Corresponding author：

YANG Jiayin, Email: docjackyang@163.com

Keywords：

liver diseases; oral microbiota; interaction

DOI：

10.7507/1007-9424.202001065

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the current status of research in the correlation between the liver diseases and oral microbiota, to provide the scientific basis for the prevention and treatment of oral diseases in the patients with liver diseases, and to provide the guidance for further research on the biomarkers for the noninvasive diagnosis of liver diseases.Method The related literatures about the studies of correlation between liver diseases and oral microbiota were reviewed by searching the databases such as the PubMed, Web of Science, CNKI, and Wanfang, etc.Results As the second richest microbiota, the oral flora closely interacted with the hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, cirrhosis, liver cancer, etc. Meanwhile, the prognosis of patients underwent liver transplantation was also closely correlated to oral flora.Conclusions Specific oral flora in patients with different liver diseases may be a potential non-invasive diagnostic biomarker. At the same time, it is necessary to pay attention to oral health and maintain oral microbiota balance for preventing and treating of liver diseases.

Citation： JI Xiao, ZENG Yanglin, GUO Yafan, KONG Lingxiang, YANG Jiayin. Research advances in correlation between liver diseases and oral microbiota. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2020, 27(9): 1163-1168. doi: 10.7507/1007-9424.202001065 Copy

1.	World Health Organization. Global hepatitis report, 2017. https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. 2019-08-25.
2.	Lu H, Ren Z, Li A, et al. Deep sequencing reveals microbiota dysbiosis of tongue coat in patients with liver carcinoma. Sci Rep, 2016, 6: 33142.
3.	Patel VC, Shawcross DL. Salivary microbiota-immune profiling in cirrhosis: could this be the noninvasive strategy that will revolutionize prognostication in hepatology? Hepatology, 2015, 62(4): 1001-1003.
4.	Ariff B, Lloyd CR, Khan S, et al. Imaging of liver cancer. World J Gastroenterol, 2009, 15(11): 1289-1300.
5.	Dewhirst FE, Chen T, Izard J, et al. The human oral microbiome. J Bacteriol, 2010, 192(19): 5002-5017.
6.	The Forsyth Institute. expanded Human Oral Microbiome Database (eHOMD). http://www.homd.org/, 2019-11-01.
7.	Solbiati J, Frias-Lopez J. Metatranscriptome of the oral microbiome in health and disease. J Dent Res, 2018, 97(5): 492-500.
8.	Yamashita Y, Takeshita T. The oral microbiome and human health. J Oral Sci, 2017, 59(2): 201-206.
9.	张怡, 逯茂洋. 口腔菌群与口腔疾病的关系的研究进展. 世界最新医学信息文摘, 2018, 18(80): 99-100.
10.	肖烨含, 李晶晶. 口腔菌群与人体疾病关系的研究进展. 世界最新医学信息文摘, 2019, 19(78): 33-34.
11.	周晓君, 易敏莉, 肖春梅. 3% 碳酸氢钠联合制霉菌素甘油及碘甘油预防肝移植术后口腔并发症及肺部感染. 护理学杂志, 2008, 23(2): 45-46.
12.	曹俊英, 包玉洁, 许洁. 口腔-肠-肝轴与肝硬化. 肝脏, 2019, 24(4): 462-464.
13.	Acharya C, Sahingur SE, Bajaj JS. Microbiota, cirrhosis, and the emerging oral-gut-liver axis. JCI Insight, 2017, 2(19): 94416.
14.	陈丽萍, 王琦. 肠道菌群与慢性肝脏疾病相关性研究进展. 中国临床研究, 2019, 32(8): 1112-1115.
15.	Socransky SS, Haffajee AD. Periodontal microbial ecology. Periodontol 2000, 2005, 38: 135-187.
16.	Li B, Ge Y, Cheng L, et al. Oral bacteria colonize and compete with gut microbiota in gnotobiotic mice. Int J Oral Sci, 2019, 11(1): 10.
17.	Grek A, Arasi L. Acute liver failure. AACN Adv Crit Care, 2016, 27(4): 420-429.
18.	National Institute of Allergy and Infectious Diseases (Niaid). Hepatitis. https://www.niaid.nih.gov/diseases-conditions/hepatitis, 2019-11-01.
19.	Griffin SO, Barker LK, Griffin PM, et al. Oral health needs among adults in the United States with chronic diseases. J Am Dent Assoc, 2009, 140(10): 1266-1274.
20.	Coates EA, Walsh L, Logan R. The increasing problem of hepatitis C virus infection. Aust Dent J, 2001, 46(1): 13-17.
21.	Drobnik A, Judd C, Banach D, et al. Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations. Am J Public Health, 2011, 101(11): 2151-2155.
22.	Ling Z, Liu X, Cheng Y, et al. Decreased diversity of the oral microbiota of patients with hepatitis B virus-induced chronic liver disease: a pilot project. Sci Rep, 2015, 5: 17098.
23.	Zhao Y, Mao YF, Tang YS, et al. Altered oral microbiota in chronic hepatitis B patients with different tongue coatings. World J Gastroenterol, 2018, 24(30): 3448-3461.
24.	Osna NA, Donohue TM Jr, Kharbanda KK. Alcoholic liver disease: pathogenesis and current management. Alcohol Res, 2017, 38(2): 147-161.
25.	Acharya C, Bajaj JS. Gut microbiota and complications of liver disease. Gastroenterol Clin North Am, 2017, 46(1): 155-169.
26.	Patel KG, Pyrsopoulos NT. Chapter 28—The microbiome and metabolome in alcoholic liver disease, microbiome and metabolome in diagnosis, therapy, and other strategic applications. Academic Press, 2019: 271-277.
27.	Liu GH, Zhao QX, Wei HY. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis. Ann Hepatol, 2019, 18(6): 796-803.
28.	Mortensen PB, Clausen MR. Short-chain fatty acids in the human colon: relation to gastrointestinal health and disease. Scand J Gastroenterol Suppl, 1996, 216: 132-148.
29.	王玉蕾, 郑跃杰. 肠道中短链脂肪酸与过敏性疾病关系的研究进展. 中国微生态学杂志, 2013, 25(1): 104-108.
30.	赵晓亚, 王跃飞, 杨帆, 等. 气相色谱法快速分析人唾液中7种短链脂肪酸. 分析化学, 2016, 44(7): 1009-1014.
31.	赵晓亚, 江振作, 王跃飞. 真性口臭的病因、分类及与疾病的关系. 北京口腔医学, 2015, 23(3): 173-176.
32.	Neuman MG, French SW, Zakhari S, et al. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage. Exp Mol Pathol, 2017, 102(1): 162-180.
33.	Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism, 2016, 65(8): 1038-1048.
34.	Yoneda M, Naka S, Nakano K, et al. Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease. BMC Gastroenterol, 2012, 12: 16.
35.	Nakahara T, Hyogo H, Ono A, et al. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease. J Gastroenterol, 2018, 53(2): 269-280.
36.	Hotamisligil GS. Inflammation and metabolic disorders. Nature, 2006, 444(7121): 860-867.
37.	Alam S, Mustafa G, Alam M, et al. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol, 2016, 7(2): 211-217.
38.	Ding LY, Liang LZ, Zhao YX, et al. Porphyromonas gingivalis-derived lipopolysaccharide causes excessive hepatic lipid accumulation via activating NF-κB and JNK signaling pathways. Oral Dis, 2019, 25(7): 1789-1797.
39.	Arimatsu K, Yamada H, Miyazawa H, et al. Oral pathobiont induces systemic inflammation and metabolic changes associated with alteration of gut microbiota. Sci Rep, 2014, 4: 4828.
40.	Komazaki R, Katagiri S, Takahashi H, et al. Periodontal pathogenic bacteria, Aggregatibacter actinomycetemcomitans affect non-alcoholic fatty liver disease by altering gut microbiota and glucose metabolism. Sci Rep, 2017, 7(1): 13950.
41.	李锐锋, 刘婉薇, 张平优, 等. 非酒精性脂肪性肝病患者和正常人群的唾液菌群的研究. 实用医学杂志, 2017, 33(21): 3593-3597.
42.	The National Institute of Diabetes and Digestive and Kidney Diseases. Cirrhosis. https://www.niddk.nih.gov/health-information/liver-disease/cirrhosis?dkrd=hispt0382, 2019-08-25.
43.	王贵强, 王福生, 成军, 等. 慢性乙型肝炎防治指南(2015更新版). 胃肠病学, 2016, 21(4): 219-240.
44.	康瑜, 陈建芳, 曾甜. 慢性乙型肝炎肝硬化患者Th22细胞和IL-22的表达及意义. 免疫学杂志, 2017, 33(2): 147-151.
45.	Bajaj JS, Betrapally NS, Hylemon PB, et al. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology, 2015, 62(4): 1260-1271.
46.	Zhang Z, Zhai H, Geng J, et al. Large-scale survey of gut microbiota associated with MHE via 16S rRNA-based pyrosequencing. Am J Gastroenterol, 2013, 108(10): 1601-1611.
47.	Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol, 2017, 14(9): 527-539.
48.	Schmalz G, Meisel A, Kollmar O, et al. Oral health-related quality of life depending on dental and periodontal health in different patients before and after liver transplantation. Clin Oral Investig, 2018, 22(5): 2039-2045.
49.	Olczak-Kowalczyk D, Kowalczyk W, Krasuska-Sławińska E, et al. Oral health and liver function in children and adolescents with cirrhosis of the liver. Prz Gastroenterol, 2014, 9(1): 24-31.
50.	Aberg F, Helenius-Hietala J, Meurman J, et al. Association between dental infections and the clinical course of chronic liver disease. Hepatol Res, 2014, 44(3): 349-353.
51.	Oikonomou T, Papatheodoridis GV, Samarkos M, et al. Clinical impact of microbiome in patients with decompensated cirrhosis. World J Gastroenterol, 2018, 24(34): 3813-3820.
52.	Gao L, Xu T, Huang G, et al. Oral microbiomes: more and more importance in oral cavity and whole body. Protein Cell, 2018, 9(5): 488-500.
53.	Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol, 2014, 60(5): 940-947.
54.	Chen Y, Yang F, Lu H, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology, 2011, 54(2): 562-572.
55.	Bajaj JS, Betrapally NS, Hylemon PB, et al. Gut microbiota alterations can predict hospitalizations in cirrhosis independent of diabetes mellitus. Sci Rep, 2015, 5: 18559.
56.	陈燕飞, 李兰娟. 肝硬化患者肠道微生态研究: 从结构到功能. 浙江大学, 2013.
57.	李佩波, 秦凡博, 龚建平. 肝硬化患者肠道屏障与细菌易位的关系. 临床肝胆病杂志, 2019, 35(8): 1854-1857.
58.	Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature, 2014, 513(7516): 59-64.
59.	Minemura M, Shimizu Y. Gut microbiota and liver diseases. World J Gastroenterol, 2015, 21(6): 1691-1702.
60.	Milosevic I, Vujovic A, Barac A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature. Int J Mol Sci, 2019, 20(2): E395.
61.	Pinzone MR, Celesia BM, Di Rosa M, et al. Microbial translocation in chronic liver diseases. Int J Microbiol, 2012, 2012: 694629.
62.	Nagpal R, Yadav H. Bacterial translocation from the gut to the distant organs: an overview. Ann Nutr Metab, 2017, 71(Suppl 1): 11-16.
63.	Lu MY, Xuan SY, Wang Z. Oral microbiota: A new view of body healt. Food Sci Human Wellness, 2019, 8(1): 8-15.
64.	Olsen I, Yamazaki K. Can oral bacteria affect the microbiome of the gut? J Oral Microbiol, 2019, 11(1): 1586422.
65.	Hyvärinen K, Tuomainen AM, Laitinen S, et al. Chlamydial and periodontal pathogens induce hepatic inflammation and fatty acid imbalance in apolipoprotein E-deficient mice. Infect Immun, 2009, 77(8): 3442-3449.
66.	黄颖, 杨玲. 原发性肝癌的高危因素及亚临床型肝癌的早期筛查. 医学新知杂志, 2014, 24(2): 73-78.
67.	陆录, 钦伦秀. 美国癌症联合委员会肝癌分期系统(第 8 版)更新解读. 中国实用外科杂志, 2017, 37(2): 141-145.
68.	Goodman B, Gardner H. The microbiome and cancer. J Pathol, 2018, 244(5): 667-676.
69.	Abe K, Fujita M, Hayashi M, et al. Gut and oral microbiota in autoimmune liver disease. Fukushima J Med Sci, 2020, 65(3): 71-75.
70.	Abe K, Takahashi A, Fujita M, et al. Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease. PLoS One, 2018, 13(7): e0198757.
71.	Wu HJ, Ivanov II, Darce J, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity, 2010, 32(6): 815-827.
72.	Shimizu J, Kubota T, Takada E, et al. Bifidobacteria abundance-featured gut microbiota compositional change in patients with Behcet’s disease. PLoS One, 2016, 11(4): e0153746.
73.	Figorilli F, Orrù G, Onali S, et al. Oral bacterial activity is significantly associated with autoimmune liver diseases and it could be involved in their pathogenesis mechanisms. J Hepatol, 2016, 64: S437.
74.	刘华娟, 余蕾, 胡亚欣, 等. 急性肝损伤小鼠口腔菌群的变化. 贵州医科大学学报, 2017, 42(5): 528-531.
75.	Ghapanchi J, Emami A, Rezazadeh F, et al. Isolation of Enterococcus faecalis in the saliva samples of patient candidates for liver transplantation. Dent Res J (Isfahan), 2019, 16(5): 333-337.
76.	Guggenheimer J, Eghtesad B, Stock DJ. Dental management of the (solid) organ transplant patient. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2003, 95(4): 383-389.
77.	Helenius-Hietala J, Aberg F, Meurman JH, et al. Increased infection risk postliver transplant without pretransplant dental treatment. Oral Dis, 2013, 19(3): 271-278.
78.	Lins L, Bittencourt PL, Evangelista MA, et al. Oral health profile of cirrhotic patients awaiting liver transplantation in the Brazilian Northeast. Transplant Proc, 2011, 43(4): 1319-1321.
79.	Santos SBD, Sabadin CES, Mario DN, et al. Presence of Candida spp. and candidiasis in liver transplant patients. An Bras Dermatol, 2018, 93(3): 356-361.
80.	Mohammed H, Varoni EM, Cochis A, et al. Oral dysbiosis in pancreatic cancer and liver cirrhosis: a review of the literature. Biomedicines, 2018, 6(4): E115.
81.	Guggenheimer J, Mayher D, Eghtesad B. A survey of dental care protocols among US organ transplant centers. Clin Transplant, 2005, 19(1): 15-18.
82.	Sun LY, Yang YS, Qu W, et al. Gut microbiota of liver transplantation recipients. Sci Rep, 2017, 7(1): 3762.
83.	Wu ZW, Ling ZX, Lu HF, et al. Changes of gut bacteria and immune parameters in liver transplant recipients. Hepatobiliary Pancreat Dis Int, 2012, 11(1): 40-50.
84.	Ziebolz D, Schmalz G, Kauffels A, et al. Periodontal pathogenic bacteria and aMMP-8 findings depending on periodontal conditions of patients before and after liver transplantation. Clin Oral Investig, 2017, 21(3): 745-752.
85.	Sheehy EC, Beighton D, Roberts GJ. The oral microbiota of children undergoing liver transplantation. Oral Microbiol Immunol, 2000, 15(3): 203-210.
86.	Kauffels A, Schmalz G, Kollmar O, et al. Oral findings and dental behaviour before and after liver transplantation—a single-centre cross-sectional study. Int Dent J, 2017, 67(4): 244-251.
87.	Guggenheimer J, Eghtesad B, Close JM, et al. Dental health status of liver transplant candidates. Liver Transpl, 2007, 13(2): 280-286.
88.	Kusterer L, Falcão LE. Oral diseases and liver pre and post-transplantation disorders. J Transpl Tech Res, 2012, 2(S): 1.

1. World Health Organization. Global hepatitis report, 2017. https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. 2019-08-25.
2. Lu H, Ren Z, Li A, et al. Deep sequencing reveals microbiota dysbiosis of tongue coat in patients with liver carcinoma. Sci Rep, 2016, 6: 33142.
3. Patel VC, Shawcross DL. Salivary microbiota-immune profiling in cirrhosis: could this be the noninvasive strategy that will revolutionize prognostication in hepatology? Hepatology, 2015, 62(4): 1001-1003.
4. Ariff B, Lloyd CR, Khan S, et al. Imaging of liver cancer. World J Gastroenterol, 2009, 15(11): 1289-1300.
5. Dewhirst FE, Chen T, Izard J, et al. The human oral microbiome. J Bacteriol, 2010, 192(19): 5002-5017.
6. The Forsyth Institute. expanded Human Oral Microbiome Database (eHOMD). http://www.homd.org/, 2019-11-01.
7. Solbiati J, Frias-Lopez J. Metatranscriptome of the oral microbiome in health and disease. J Dent Res, 2018, 97(5): 492-500.
8. Yamashita Y, Takeshita T. The oral microbiome and human health. J Oral Sci, 2017, 59(2): 201-206.
9. 张怡, 逯茂洋. 口腔菌群与口腔疾病的关系的研究进展. 世界最新医学信息文摘, 2018, 18(80): 99-100.
10. 肖烨含, 李晶晶. 口腔菌群与人体疾病关系的研究进展. 世界最新医学信息文摘, 2019, 19(78): 33-34.
11. 周晓君, 易敏莉, 肖春梅. 3% 碳酸氢钠联合制霉菌素甘油及碘甘油预防肝移植术后口腔并发症及肺部感染. 护理学杂志, 2008, 23(2): 45-46.
12. 曹俊英, 包玉洁, 许洁. 口腔-肠-肝轴与肝硬化. 肝脏, 2019, 24(4): 462-464.
13. Acharya C, Sahingur SE, Bajaj JS. Microbiota, cirrhosis, and the emerging oral-gut-liver axis. JCI Insight, 2017, 2(19): 94416.
14. 陈丽萍, 王琦. 肠道菌群与慢性肝脏疾病相关性研究进展. 中国临床研究, 2019, 32(8): 1112-1115.
15. Socransky SS, Haffajee AD. Periodontal microbial ecology. Periodontol 2000, 2005, 38: 135-187.
16. Li B, Ge Y, Cheng L, et al. Oral bacteria colonize and compete with gut microbiota in gnotobiotic mice. Int J Oral Sci, 2019, 11(1): 10.
17. Grek A, Arasi L. Acute liver failure. AACN Adv Crit Care, 2016, 27(4): 420-429.
18. National Institute of Allergy and Infectious Diseases (Niaid). Hepatitis. https://www.niaid.nih.gov/diseases-conditions/hepatitis, 2019-11-01.
19. Griffin SO, Barker LK, Griffin PM, et al. Oral health needs among adults in the United States with chronic diseases. J Am Dent Assoc, 2009, 140(10): 1266-1274.
20. Coates EA, Walsh L, Logan R. The increasing problem of hepatitis C virus infection. Aust Dent J, 2001, 46(1): 13-17.
21. Drobnik A, Judd C, Banach D, et al. Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations. Am J Public Health, 2011, 101(11): 2151-2155.
22. Ling Z, Liu X, Cheng Y, et al. Decreased diversity of the oral microbiota of patients with hepatitis B virus-induced chronic liver disease: a pilot project. Sci Rep, 2015, 5: 17098.
23. Zhao Y, Mao YF, Tang YS, et al. Altered oral microbiota in chronic hepatitis B patients with different tongue coatings. World J Gastroenterol, 2018, 24(30): 3448-3461.
24. Osna NA, Donohue TM Jr, Kharbanda KK. Alcoholic liver disease: pathogenesis and current management. Alcohol Res, 2017, 38(2): 147-161.
25. Acharya C, Bajaj JS. Gut microbiota and complications of liver disease. Gastroenterol Clin North Am, 2017, 46(1): 155-169.
26. Patel KG, Pyrsopoulos NT. Chapter 28—The microbiome and metabolome in alcoholic liver disease, microbiome and metabolome in diagnosis, therapy, and other strategic applications. Academic Press, 2019: 271-277.
27. Liu GH, Zhao QX, Wei HY. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis. Ann Hepatol, 2019, 18(6): 796-803.
28. Mortensen PB, Clausen MR. Short-chain fatty acids in the human colon: relation to gastrointestinal health and disease. Scand J Gastroenterol Suppl, 1996, 216: 132-148.
29. 王玉蕾, 郑跃杰. 肠道中短链脂肪酸与过敏性疾病关系的研究进展. 中国微生态学杂志, 2013, 25(1): 104-108.
30. 赵晓亚, 王跃飞, 杨帆, 等. 气相色谱法快速分析人唾液中7种短链脂肪酸. 分析化学, 2016, 44(7): 1009-1014.
31. 赵晓亚, 江振作, 王跃飞. 真性口臭的病因、分类及与疾病的关系. 北京口腔医学, 2015, 23(3): 173-176.
32. Neuman MG, French SW, Zakhari S, et al. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage. Exp Mol Pathol, 2017, 102(1): 162-180.
33. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism, 2016, 65(8): 1038-1048.
34. Yoneda M, Naka S, Nakano K, et al. Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease. BMC Gastroenterol, 2012, 12: 16.
35. Nakahara T, Hyogo H, Ono A, et al. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease. J Gastroenterol, 2018, 53(2): 269-280.
36. Hotamisligil GS. Inflammation and metabolic disorders. Nature, 2006, 444(7121): 860-867.
37. Alam S, Mustafa G, Alam M, et al. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol, 2016, 7(2): 211-217.
38. Ding LY, Liang LZ, Zhao YX, et al. Porphyromonas gingivalis-derived lipopolysaccharide causes excessive hepatic lipid accumulation via activating NF-κB and JNK signaling pathways. Oral Dis, 2019, 25(7): 1789-1797.
39. Arimatsu K, Yamada H, Miyazawa H, et al. Oral pathobiont induces systemic inflammation and metabolic changes associated with alteration of gut microbiota. Sci Rep, 2014, 4: 4828.
40. Komazaki R, Katagiri S, Takahashi H, et al. Periodontal pathogenic bacteria, Aggregatibacter actinomycetemcomitans affect non-alcoholic fatty liver disease by altering gut microbiota and glucose metabolism. Sci Rep, 2017, 7(1): 13950.
41. 李锐锋, 刘婉薇, 张平优, 等. 非酒精性脂肪性肝病患者和正常人群的唾液菌群的研究. 实用医学杂志, 2017, 33(21): 3593-3597.
42. The National Institute of Diabetes and Digestive and Kidney Diseases. Cirrhosis. https://www.niddk.nih.gov/health-information/liver-disease/cirrhosis?dkrd=hispt0382, 2019-08-25.
43. 王贵强, 王福生, 成军, 等. 慢性乙型肝炎防治指南(2015更新版). 胃肠病学, 2016, 21(4): 219-240.
44. 康瑜, 陈建芳, 曾甜. 慢性乙型肝炎肝硬化患者Th22细胞和IL-22的表达及意义. 免疫学杂志, 2017, 33(2): 147-151.
45. Bajaj JS, Betrapally NS, Hylemon PB, et al. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology, 2015, 62(4): 1260-1271.
46. Zhang Z, Zhai H, Geng J, et al. Large-scale survey of gut microbiota associated with MHE via 16S rRNA-based pyrosequencing. Am J Gastroenterol, 2013, 108(10): 1601-1611.
47. Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol, 2017, 14(9): 527-539.
48. Schmalz G, Meisel A, Kollmar O, et al. Oral health-related quality of life depending on dental and periodontal health in different patients before and after liver transplantation. Clin Oral Investig, 2018, 22(5): 2039-2045.
49. Olczak-Kowalczyk D, Kowalczyk W, Krasuska-Sławińska E, et al. Oral health and liver function in children and adolescents with cirrhosis of the liver. Prz Gastroenterol, 2014, 9(1): 24-31.
50. Aberg F, Helenius-Hietala J, Meurman J, et al. Association between dental infections and the clinical course of chronic liver disease. Hepatol Res, 2014, 44(3): 349-353.
51. Oikonomou T, Papatheodoridis GV, Samarkos M, et al. Clinical impact of microbiome in patients with decompensated cirrhosis. World J Gastroenterol, 2018, 24(34): 3813-3820.
52. Gao L, Xu T, Huang G, et al. Oral microbiomes: more and more importance in oral cavity and whole body. Protein Cell, 2018, 9(5): 488-500.
53. Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol, 2014, 60(5): 940-947.
54. Chen Y, Yang F, Lu H, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology, 2011, 54(2): 562-572.
55. Bajaj JS, Betrapally NS, Hylemon PB, et al. Gut microbiota alterations can predict hospitalizations in cirrhosis independent of diabetes mellitus. Sci Rep, 2015, 5: 18559.
56. 陈燕飞, 李兰娟. 肝硬化患者肠道微生态研究: 从结构到功能. 浙江大学, 2013.
57. 李佩波, 秦凡博, 龚建平. 肝硬化患者肠道屏障与细菌易位的关系. 临床肝胆病杂志, 2019, 35(8): 1854-1857.
58. Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature, 2014, 513(7516): 59-64.
59. Minemura M, Shimizu Y. Gut microbiota and liver diseases. World J Gastroenterol, 2015, 21(6): 1691-1702.
60. Milosevic I, Vujovic A, Barac A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature. Int J Mol Sci, 2019, 20(2): E395.
61. Pinzone MR, Celesia BM, Di Rosa M, et al. Microbial translocation in chronic liver diseases. Int J Microbiol, 2012, 2012: 694629.
62. Nagpal R, Yadav H. Bacterial translocation from the gut to the distant organs: an overview. Ann Nutr Metab, 2017, 71(Suppl 1): 11-16.
63. Lu MY, Xuan SY, Wang Z. Oral microbiota: A new view of body healt. Food Sci Human Wellness, 2019, 8(1): 8-15.
64. Olsen I, Yamazaki K. Can oral bacteria affect the microbiome of the gut? J Oral Microbiol, 2019, 11(1): 1586422.
65. Hyvärinen K, Tuomainen AM, Laitinen S, et al. Chlamydial and periodontal pathogens induce hepatic inflammation and fatty acid imbalance in apolipoprotein E-deficient mice. Infect Immun, 2009, 77(8): 3442-3449.
66. 黄颖, 杨玲. 原发性肝癌的高危因素及亚临床型肝癌的早期筛查. 医学新知杂志, 2014, 24(2): 73-78.
67. 陆录, 钦伦秀. 美国癌症联合委员会肝癌分期系统(第 8 版)更新解读. 中国实用外科杂志, 2017, 37(2): 141-145.
68. Goodman B, Gardner H. The microbiome and cancer. J Pathol, 2018, 244(5): 667-676.
69. Abe K, Fujita M, Hayashi M, et al. Gut and oral microbiota in autoimmune liver disease. Fukushima J Med Sci, 2020, 65(3): 71-75.
70. Abe K, Takahashi A, Fujita M, et al. Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease. PLoS One, 2018, 13(7): e0198757.
71. Wu HJ, Ivanov II, Darce J, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity, 2010, 32(6): 815-827.
72. Shimizu J, Kubota T, Takada E, et al. Bifidobacteria abundance-featured gut microbiota compositional change in patients with Behcet’s disease. PLoS One, 2016, 11(4): e0153746.
73. Figorilli F, Orrù G, Onali S, et al. Oral bacterial activity is significantly associated with autoimmune liver diseases and it could be involved in their pathogenesis mechanisms. J Hepatol, 2016, 64: S437.
74. 刘华娟, 余蕾, 胡亚欣, 等. 急性肝损伤小鼠口腔菌群的变化. 贵州医科大学学报, 2017, 42(5): 528-531.
75. Ghapanchi J, Emami A, Rezazadeh F, et al. Isolation of Enterococcus faecalis in the saliva samples of patient candidates for liver transplantation. Dent Res J (Isfahan), 2019, 16(5): 333-337.
76. Guggenheimer J, Eghtesad B, Stock DJ. Dental management of the (solid) organ transplant patient. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2003, 95(4): 383-389.
77. Helenius-Hietala J, Aberg F, Meurman JH, et al. Increased infection risk postliver transplant without pretransplant dental treatment. Oral Dis, 2013, 19(3): 271-278.
78. Lins L, Bittencourt PL, Evangelista MA, et al. Oral health profile of cirrhotic patients awaiting liver transplantation in the Brazilian Northeast. Transplant Proc, 2011, 43(4): 1319-1321.
79. Santos SBD, Sabadin CES, Mario DN, et al. Presence of Candida spp. and candidiasis in liver transplant patients. An Bras Dermatol, 2018, 93(3): 356-361.
80. Mohammed H, Varoni EM, Cochis A, et al. Oral dysbiosis in pancreatic cancer and liver cirrhosis: a review of the literature. Biomedicines, 2018, 6(4): E115.
81. Guggenheimer J, Mayher D, Eghtesad B. A survey of dental care protocols among US organ transplant centers. Clin Transplant, 2005, 19(1): 15-18.
82. Sun LY, Yang YS, Qu W, et al. Gut microbiota of liver transplantation recipients. Sci Rep, 2017, 7(1): 3762.
83. Wu ZW, Ling ZX, Lu HF, et al. Changes of gut bacteria and immune parameters in liver transplant recipients. Hepatobiliary Pancreat Dis Int, 2012, 11(1): 40-50.
84. Ziebolz D, Schmalz G, Kauffels A, et al. Periodontal pathogenic bacteria and aMMP-8 findings depending on periodontal conditions of patients before and after liver transplantation. Clin Oral Investig, 2017, 21(3): 745-752.
85. Sheehy EC, Beighton D, Roberts GJ. The oral microbiota of children undergoing liver transplantation. Oral Microbiol Immunol, 2000, 15(3): 203-210.
86. Kauffels A, Schmalz G, Kollmar O, et al. Oral findings and dental behaviour before and after liver transplantation—a single-centre cross-sectional study. Int Dent J, 2017, 67(4): 244-251.
87. Guggenheimer J, Eghtesad B, Close JM, et al. Dental health status of liver transplant candidates. Liver Transpl, 2007, 13(2): 280-286.
88. Kusterer L, Falcão LE. Oral diseases and liver pre and post-transplantation disorders. J Transpl Tech Res, 2012, 2(S): 1.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research advances in correlation between liver diseases and oral microbiota

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content